Leiden University Scholarly Publications

Persistent URL of this record https://hdl.handle.net/1887/3202915

In Collections

This item can be found in the following collections:

Buijs, J.T.; Laghman, E.H.; Akker, R.F.P. van den; Tieken, C.; Vletter, E.; Molen, K. van der; ... ; Versteeg, H.H. (2018)

Direct oral anticoagulants do not inhibit growth and metastasis of human triple negative breast cancer in immunodeficient mice

Article / Letter to editor
It has been well-established that cancer results in a hypercoagulable state and an increased risk for venous thromboembolism (VTE). More recently, it has been suggested that coagulation may also affect cancer progression and metastasis. Cancer patients with VTE are currently treated with the anticoagulant...Show moreIt has been well-established that cancer results in a hypercoagulable state and an increased risk for venous thromboembolism (VTE). More recently, it has been suggested that coagulation may also affect cancer progression and metastasis. Cancer patients with VTE are currently treated with the anticoagulant low molecular weight heparins (LMWHs). Preclinical studies have shown that LMWHs can inhibit metastasis formation in several types of cancer, but beneficial effects of LMWHs on survival have not been consistently found in clinical trials. Recently, a new class of anticoagulants are available for treatment of VTE, the so-called direct oral anticoagulant (DOACs), which include dabigatran and rivaroxaban, a direct thrombin and FXa inhibitor, respectively. However, the effects of DOACs on cancer are currently under studied.Show less
All authors
Buijs, J.T.; Laghman, E.H.; Akker, R.F.P. van den; Tieken, C.; Vletter, E.; Molen, K. van der; Crooijmans, J.; Kroone, C.; Pluijm, G. van der; Le Devedec, S.E.; Versteeg, H.H.
Date
2018-04-01
Volume
164
Issue
1
Pages
S221 - S222
DOI
doi:10.1016/j.thromres.2018.02.091